Transient cerebral ischaemic attacks--management and prognosis

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Transient ischemic attack (TIA) is a critical warning sign for future stroke.
• Effective preventative strategies for TIA patients are crucial to reduce long-term neurological morbidity.

Purpose of the Study:

• To evaluate the efficacy of sulfinpyrazone in preventing recurrent transient ischemic attacks (TIAs).
• To assess the long-term impact of early TIA recurrence on subsequent neurological events.

Main Methods:

• A double-blind, placebo-controlled, cross-over trial involving 50 patients with recent TIAs.
• Patients received either sulfinpyrazone (200 mg 4 times daily) or placebo for 4-month periods.
• Follow-up data were collected for up to 2 years on 39 patients.

Main Results:

• No significant difference in TIA recurrence rates was observed between sulfinpyrazone and placebo groups during the 8-month trial.
• A higher incidence of recurrences was noted in the initial 4 months of the study.
• Long-term follow-up revealed that 90% of patients without early recurrences remained free of further neurological events, compared to only 47% of those who experienced recurrences.

Conclusions:

• Sulfinpyrazone did not demonstrate efficacy in preventing short-term TIA recurrences.
• Absence of early TIA recurrence is a strong predictor of favorable long-term neurological outcomes.
• Further research may be needed to identify effective treatments for TIA prevention.